NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ZYME

Zymeworks BC Inc

Jun 03 • 04:00PM ET

12.08

Dollar change +0.44
Percentage change 3.78	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD REGN VRTX INCY ALNY EXEL NBIX IONS

| Held by: VTI IWM IWN IBB VTWO DFAS VHT DFAC IWC BSVO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.50	Insider Own	3.58%	Shs Outstand	69.58M	Perf Week	7.66%
Market Cap	848.66M	Forward P/E	-	EPS next Y	-1.10	Insider Trans	123.34%	Shs Float	67.74M	Perf Month	-6.79%
Income	-113.68M	PEG	-	EPS next Q	-0.48	Inst Own	101.93%	Short Float	10.03%	Perf Quarter	-5.25%
Sales	93.38M	P/S	9.09	EPS this Y	1.74%	Inst Trans	6.41%	Short Ratio	10.25	Perf Half Y	-16.23%
Book/sh	4.63	P/B	2.61	EPS next Y	30.71%	ROA	-23.22%	Short Interest	6.79M	Perf Year	43.30%
Cash/sh	3.78	P/C	3.20	EPS next 5Y	-0.98%	ROE	-29.80%	52W Range	8.21 - 17.70	Perf YTD	-17.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.81%	ROI	-33.42%	52W High	-31.75%	Beta	1.17
Dividend TTM	-	Quick Ratio	4.71	Sales past 5Y	20.90%	Gross Margin	86.95%	52W Low	47.14%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	4.71	EPS Y/Y TTM	15.96%	Oper. Margin	-115.26%	RSI (14)	54.60	Volatility	1.34% 3.59%
Employees	286	Debt/Eq	0.06	Sales Y/Y TTM	85.05%	Profit Margin	-121.73%	Recom	1.40	Target Price	21.56
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	27.42%	Payout	-	Rel Volume	0.48	Prev Close	11.64
Sales Surprise	31.53%	EPS Surprise	56.11%	Sales Q/Q	170.29%	Earnings	May 08 AMC	Avg Volume	662.66K	Price	12.08
SMA20	4.14%	SMA50	2.88%	SMA200	-7.25%	Trades		Volume	317,263	Change	3.78%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight	$18
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform	$10 → $25
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32
Mar-31-21	Initiated	Credit Suisse	Outperform	$55
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$41
Feb-08-21	Resumed	H.C. Wainwright	Buy	$57
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$50 → $53
Sep-29-20	Resumed	JP Morgan	Neutral	$48

Show Previous Ratings

May-30-25 06:00AM	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer (GlobeNewswire)
May-22-25 05:00PM	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences (GlobeNewswire)
May-21-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-25 04:15PM	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference (GlobeNewswire) +5.16%
May-14-25 09:55AM	Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet (Zacks)
05:50PM	Loading…
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 10:35AM	Zymeworks Inc (ZYME) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
10:48AM	Zymeworks: Poised For Growth With Platform Validation (Seeking Alpha)
Apr-25-25 01:00PM	Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting (GlobeNewswire)
Apr-21-25 06:00AM	Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development (GlobeNewswire)
Apr-17-25 06:00AM	Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire)
Apr-09-25 10:13AM	Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey)
11:00AM	Loading…
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 04:30PM	Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting (GlobeNewswire)
10:49AM	Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-05-25 04:05PM	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -7.97%
Mar-04-25 07:09AM	Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-26-25 06:00AM	Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration (GlobeNewswire)
Feb-25-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-18-25 06:00AM	Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors (GlobeNewswire)
Feb-13-25 06:00AM	Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 (GlobeNewswire)
Jan-30-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-08-25 04:05PM	Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 (GlobeNewswire) -6.44%
Dec-12-24 08:30AM	Zymeworks Hosts RandD Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
08:30AM	Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-21-24 06:05AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.98%
06:00AM	Loading…
06:00AM	FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) (GlobeNewswire)
Nov-05-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors (GlobeNewswire)
Oct-31-24 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:14AM	Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-24 06:00AM	Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Oct-21-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers (GlobeNewswire)
Oct-10-24 06:30AM	Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-18-24 06:00AM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Sep-03-24 04:30PM	Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) (GlobeNewswire)
Aug-22-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 04:10PM	Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock (GlobeNewswire)
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-24 04:30PM	Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer (GlobeNewswire)
Jul-22-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor- Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-11-24 06:30AM	Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 (GlobeNewswire) +6.82%
Jun-17-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers (GlobeNewswire) -5.53%
Jun-10-24 06:00AM	Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer (GlobeNewswire)
May-28-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-16-24 04:20PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME) (Business Wire)
May-02-24 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-11-24 06:00AM	Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Apr-10-24 09:35AM	Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-08-24 06:00AM	Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-28-24 06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-24 12:00PM	Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-07-24 06:39AM	Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape' (FierceBiotech.com) -6.46%
Mar-06-24 10:53PM	ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:09PM	Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.51%
Feb-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 06:00AM	Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call (GlobeNewswire)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Feb-08-24 06:00AM	Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors (GlobeNewswire)
Jan-31-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-11-24 12:00PM	Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know (Zacks)
Jan-04-24 06:15AM	Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 (GlobeNewswire)
06:00AM	Zymeworks Announces Additional Leadership Appointments (GlobeNewswire)
Dec-26-23 08:00AM	Zymeworks Announces $50 Million Private Placement to EcoR1 Capital (GlobeNewswire) +8.65%
Dec-15-23 08:30AM	Zymeworks Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-08-23 10:11AM	5 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Nov-30-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Nov-08-23 05:33PM	Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-23 08:30AM	Zymeworks To Host Third Quarter 2023 Results Conference Call (GlobeNewswire)
Oct-16-23 04:30PM	Zymeworks Announces New Director Nominee (GlobeNewswire) +8.46%
Aug-10-23 04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -7.60%
Aug-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-19-23 08:30AM	Zymeworks To Host Second Quarter 2023 Results Conference Call (GlobeNewswire)
Jul-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Jun-29-23 04:05PM	Zymeworks Appoints New Director (GlobeNewswire)
Jun-26-23 08:30AM	Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes (GlobeNewswire)
Jun-02-23 06:41PM	Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers (PR Newswire)
Jun-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:30AM	Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer (GlobeNewswire)
May-08-23 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) +12.79%
May-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-23 04:05PM	Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-17-23 08:30AM	Zymeworks To Host First Quarter 2023 Results Conference Call (Business Wire)
Apr-10-23 08:30AM	Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors (Business Wire)
Apr-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	Director	May 15 '25	Buy	11.43	49,502	565,847	17,877,989	May 19 06:35 PM
EcoR1 Capital, LLC	Director	May 19 '25	Buy	11.78	5,919	69,738	17,883,908	May 19 06:35 PM
EcoR1 Capital, LLC	Director	Apr 16 '25	Buy	11.16	73,953	825,589	17,773,727	Apr 18 03:17 PM
EcoR1 Capital, LLC	Director	Apr 17 '25	Buy	11.52	54,760	630,819	17,828,487	Apr 18 03:17 PM
EcoR1 Capital, LLC	Director	Apr 04 '25	Buy	11.17	196,438	2,193,800	17,699,774	Apr 07 06:34 PM
EcoR1 Capital, LLC	Director	Apr 03 '25	Buy	11.84	120,770	1,430,170	17,503,336	Apr 07 06:34 PM
EcoR1 Capital, LLC	Director	Apr 02 '25	Buy	11.85	74,360	881,017	17,382,566	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Apr 01 '25	Buy	11.60	48,658	564,647	17,308,206	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Mar 31 '25	Buy	11.75	4,397	51,658	17,259,548	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Mar 25 '25	Buy	12.91	53,501	690,452	17,211,303	Mar 27 06:53 PM
EcoR1 Capital, LLC	Director	Mar 26 '25	Buy	12.24	43,848	536,857	17,255,151	Mar 27 06:53 PM
EcoR1 Capital, LLC	Director	Mar 20 '25	Buy	12.93	73,476	949,883	17,104,080	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 21 '25	Buy	12.78	31,033	396,518	17,135,113	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 24 '25	Buy	13.08	22,689	296,847	17,157,802	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 18 '25	Buy	12.65	113,880	1,440,855	16,972,298	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 19 '25	Buy	12.64	58,306	737,233	17,030,604	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 17 '25	Buy	12.23	56,277	688,465	16,858,418	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 13 '25	Buy	12.48	468,356	5,847,237	16,802,141	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Mar 11 '25	Buy	11.49	320,690	3,685,851	16,040,851	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Mar 12 '25	Buy	12.25	292,934	3,587,826	16,333,785	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Jan 16 '25	Buy	13.88	121,681	1,689,541	15,700,413	Jan 21 05:34 PM
EcoR1 Capital, LLC	Director	Jan 17 '25	Buy	13.87	19,748	273,998	15,720,161	Jan 21 05:34 PM
EcoR1 Capital, LLC	Director	Jan 13 '25	Buy	13.39	74,125	992,875	15,485,203	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 14 '25	Buy	13.56	54,500	739,265	15,539,703	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 15 '25	Buy	14.01	39,029	546,671	15,578,732	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 10 '25	Buy	13.13	204,098	2,678,990	15,411,078	Jan 10 06:27 PM
EcoR1 Capital, LLC	Director	Jan 08 '25	Buy	14.07	21,021	295,829	15,206,980	Jan 10 06:27 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Option Exercise	0.00	37,166	0	34,741	Jan 06 08:35 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Sale	14.92	21,200	316,391	14,741	Jan 06 08:35 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Option Exercise	0.00	114,332	0	114,209	Jan 06 08:34 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Sale	14.92	57,291	855,017	47,543	Jan 06 08:34 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Option Exercise	0.00	20,000	0	20,000	Jan 06 08:19 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Sale	14.92	11,110	165,807	8,890	Jan 06 08:19 PM
Smith Jeffrey T L	Officer	Jan 06 '25	Proposed Sale	14.46	11,110	160,651		Jan 06 07:50 PM
Moore Paul Andrew	Officer	Jan 06 '25	Proposed Sale	14.46	21,200	306,552		Jan 06 07:43 PM
Galbraith, Kenneth	Officer	Jan 06 '25	Proposed Sale	14.46	57,291	828,428		Jan 06 07:37 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	14.78	157,880	2,333,403	15,185,959	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	14.57	146,501	2,134,446	15,028,079	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	14.47	58,988	853,326	14,881,578	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 27 '24	Buy	14.49	101,659	1,473,181	14,822,590	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 26 '24	Buy	14.38	16,692	240,038	14,720,931	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 24 '24	Buy	14.12	11,958	168,896	14,704,239	Dec 27 06:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYME

Zymeworks BC Inc

Upgrade your FINVIZ experience